As ADCs and other targeted therapies continue to evolve, integrating imaging measures, like Nectin-4 PET for EV, could redefine dose selection strategies, improve patient outcomes, and accelerate the development of next-generation cancer treatments. The gene discussed is NECTIN1; the disease is cancer.